BusinessFeb 24, 2026
Novo Nordisk Slashes Wegovy and Ozempic Prices Up to 50% Starting 2027
Pharma Strategy
Rhea Lobo
Big Pharma’s weight loss boom is about to get cheaper. Novo Nordisk plans to cut US list prices for its blockbuster diabetes and obesity drugs Ozempic and Wegovy by as much as 50%, starting Jan. 1, 2027. The move sharply escalates an already fierce pricing war as competition heats up in the red-hot GLP-1 market.
- Novo Nordisk’s first-ever list price cut targets patients with high-deductible or coinsurance plans facing steep out-of-pocket costs.
- Rival Eli Lilly currently dominates the competitive landscape despite Novo’s early market advantage, prompting it to adopt an aggressive pricing strategy to regain lost ground.
Pricing the cure: Novo Nordisk’s Jamey Millar says, “Our hope is that reduced prices will lead to better access and affordability.” The move aligns neatly with new Medicare-negotiated prices of $274 for a 30-day supply, which take effect at the same time. With millions already using GLP-1 drugs and many more blocked by cost, the move could widen access and accelerate broader adoption. In this market, access is the advantage.
